Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

An activatable PET imaging radioprobe is a dynamic reporter of myeloperoxidase activity in vivo.

Wang C, Keliher E, Zeller MWG, Wojtkiewicz GR, Aguirre AD, Buckbinder L, Kim HY, Chen J, Maresca K, Ahmed MS, Motlagh NJ, Nahrendorf M, Chen JW.

Proc Natl Acad Sci U S A. 2019 Jun 11;116(24):11966-11971. doi: 10.1073/pnas.1818434116. Epub 2019 May 23.

PMID:
31123149
2.

Myeloperoxidase inhibition in mice alters atherosclerotic lesion composition.

Roth Flach RJ, Su C, Bollinger E, Cortes C, Robertson AW, Opsahl AC, Coskran TM, Maresca KP, Keliher EJ, Yates PD, Kim AM, Kalgutkar AS, Buckbinder L.

PLoS One. 2019 Mar 19;14(3):e0214150. doi: 10.1371/journal.pone.0214150. eCollection 2019.

3.

2-Aminopyridine-Based Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4) Inhibitors: Assessment of Mechanism-Based Safety.

Dow RL, Ammirati M, Bagley SW, Bhattacharya SK, Buckbinder L, Cortes C, El-Kattan AF, Ford K, Freeman GB, Guimarães CRW, Liu S, Niosi M, Skoura A, Tess D.

J Med Chem. 2018 Apr 12;61(7):3114-3125. doi: 10.1021/acs.jmedchem.8b00152. Epub 2018 Apr 3.

PMID:
29570292
4.

Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome.

Dong JQ, Gosset JR, Fahmi OA, Lin Z, Chabot JR, Terra SG, Le V, Chidsey K, Nouri P, Kim A, Buckbinder L, Kalgutkar AS.

Drug Metab Dispos. 2017 May;45(5):501-511. doi: 10.1124/dmd.116.074476. Epub 2017 Mar 2.

PMID:
28254951
5.

Myeloperoxidase Inhibition Improves Ventricular Function and Remodeling After Experimental Myocardial Infarction.

Ali M, Pulli B, Courties G, Tricot B, Sebas M, Iwamoto Y, Hilgendorf I, Schob S, Dong A, Zheng W, Skoura A, Kalgukar A, Cortes C, Ruggeri R, Swirski FK, Nahrendorf M, Buckbinder L, Chen JW.

JACC Basic Transl Sci. 2016 Dec 26;1(7):633-643. doi: 10.1016/j.jacbts.2016.09.004. eCollection 2016 Dec. Review.

6.

Species Differences in the Oxidative Desulfurization of a Thiouracil-Based Irreversible Myeloperoxidase Inactivator by Flavin-Containing Monooxygenase Enzymes.

Eng H, Sharma R, Wolford A, Di L, Ruggeri RB, Buckbinder L, Conn EL, Dalvie DK, Kalgutkar AS.

Drug Metab Dispos. 2016 Aug;44(8):1262-9. doi: 10.1124/dmd.116.070185. Epub 2016 Apr 14.

PMID:
27079250
7.

Endothelial protein kinase MAP4K4 promotes vascular inflammation and atherosclerosis.

Roth Flach RJ, Skoura A, Matevossian A, Danai LV, Zheng W, Cortes C, Bhattacharya SK, Aouadi M, Hagan N, Yawe JC, Vangala P, Menendez LG, Cooper MP, Fitzgibbons TP, Buckbinder L, Czech MP.

Nat Commun. 2015 Dec 21;6:8995. doi: 10.1038/ncomms9995.

8.

Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment.

Ammirati M, Bagley SW, Bhattacharya SK, Buckbinder L, Carlo AA, Conrad R, Cortes C, Dow RL, Dowling MS, El-Kattan A, Ford K, Guimarães CR, Hepworth D, Jiao W, LaPerle J, Liu S, Londregan A, Loria PM, Mathiowetz AM, Munchhof M, Orr ST, Petersen DN, Price DA, Skoura A, Smith AC, Wang J.

ACS Med Chem Lett. 2015 Oct 6;6(11):1128-33. doi: 10.1021/acsmedchemlett.5b00215. eCollection 2015 Nov 12.

9.

Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases.

Ruggeri RB, Buckbinder L, Bagley SW, Carpino PA, Conn EL, Dowling MS, Fernando DP, Jiao W, Kung DW, Orr ST, Qi Y, Rocke BN, Smith A, Warmus JS, Zhang Y, Bowles D, Widlicka DW, Eng H, Ryder T, Sharma R, Wolford A, Okerberg C, Walters K, Maurer TS, Zhang Y, Bonin PD, Spath SN, Xing G, Hepworth D, Ahn K, Kalgutkar AS.

J Med Chem. 2015 Nov 12;58(21):8513-28. doi: 10.1021/acs.jmedchem.5b00963. Epub 2015 Oct 28.

PMID:
26509551
10.

MAP4K4 Is a Threonine Kinase That Phosphorylates FARP1.

Schwaid AG, Su C, Loos P, Wu J, Nguyen C, Stone KL, Kanyo J, Geoghegan KF, Bhattacharya SK, Dow RL, Buckbinder L, Carpino PA.

ACS Chem Biol. 2015 Dec 18;10(12):2667-71. doi: 10.1021/acschembio.5b00679. Epub 2015 Sep 30.

PMID:
26422651
11.

2-Aryl-3-methyloctahydrophenanthrene-2,3,7-triols as potent dissociated glucocorticoid receptor agonists.

Chantigny YA, Murray JC, Kleinman EF, Robinson RP, Plotkin MA, Reese MR, Buckbinder L, McNiff PA, Millham ML, Schaefer JF, Abramov YA, Bordner J.

J Med Chem. 2015 Mar 26;58(6):2658-77. doi: 10.1021/jm501601b. Epub 2015 Mar 17.

PMID:
25706100
12.

PF-1355, a mechanism-based myeloperoxidase inhibitor, prevents immune complex vasculitis and anti-glomerular basement membrane glomerulonephritis.

Zheng W, Warner R, Ruggeri R, Su C, Cortes C, Skoura A, Ward J, Ahn K, Kalgutkar A, Sun D, Maurer TS, Bonin PD, Okerberg C, Bobrowski W, Kawabe T, Zhang Y, Coskran T, Bell S, Kapoor B, Johnson K, Buckbinder L.

J Pharmacol Exp Ther. 2015 May;353(2):288-98. doi: 10.1124/jpet.114.221788. Epub 2015 Feb 19.

PMID:
25698787
13.

PYK2 selectively mediates signals for growth versus differentiation in response to stretch of spontaneously active vascular smooth muscle.

Bhattachariya A, Turczyńska KM, Grossi M, Nordström I, Buckbinder L, Albinsson S, Hellstrand P.

Physiol Rep. 2014 Jul 16;2(7). pii: e12080. doi: 10.14814/phy2.12080.

14.

Toxicities associated with 1-month treatment with propylthiouracil (PTU) and methimazole (MMI) in male rats.

Nambiar PR, Palanisamy GS, Okerberg C, Wolford A, Walters K, Buckbinder L, Reagan WJ.

Toxicol Pathol. 2014 Aug;42(6):970-83. doi: 10.1177/0192623313502708. Epub 2013 Sep 25.

PMID:
24067673
15.

Identification of novel series of pyrazole and indole-urea based DFG-out PYK2 inhibitors.

Bhattacharya SK, Aspnes GE, Bagley SW, Boehm M, Brosius AD, Buckbinder L, Chang JS, Dibrino J, Eng H, Frederick KS, Griffith DA, Griffor MC, Guimarães CR, Guzman-Perez A, Han S, Kalgutkar AS, Klug-McLeod J, Garcia-Irizarry C, Li J, Lippa B, Price DA, Southers JA, Walker DP, Wei L, Xiao J, Zawistoski MP, Zhao X.

Bioorg Med Chem Lett. 2012 Dec 15;22(24):7523-9. doi: 10.1016/j.bmcl.2012.10.039. Epub 2012 Oct 16.

PMID:
23153798
16.

Small molecule inhibitors of the Pyk2 and FAK kinases modulate chemoattractant-induced migration, adhesion and Akt activation in follicular and marginal zone B cells.

Tse KW, Lin KB, Dang-Lawson M, Guzman-Perez A, Aspnes GE, Buckbinder L, Gold MR.

Cell Immunol. 2012 Jan-Feb;275(1-2):47-54. doi: 10.1016/j.cellimm.2012.03.002. Epub 2012 Mar 29.

PMID:
22507871
17.

Decreased cell adhesion promotes angiogenesis in a Pyk2-dependent manner.

Shen CJ, Raghavan S, Xu Z, Baranski JD, Yu X, Wozniak MA, Miller JS, Gupta M, Buckbinder L, Chen CS.

Exp Cell Res. 2011 Aug 1;317(13):1860-71. doi: 10.1016/j.yexcr.2011.05.006. Epub 2011 May 18.

18.

Understanding the impact of the P-loop conformation on kinase selectivity.

Guimarães CR, Rai BK, Munchhof MJ, Liu S, Wang J, Bhattacharya SK, Buckbinder L.

J Chem Inf Model. 2011 Jun 27;51(6):1199-204. doi: 10.1021/ci200153c. Epub 2011 May 24.

PMID:
21568278
19.

Phosphoproteomic characterization of PYK2 signaling pathways involved in osteogenesis.

Bonnette PC, Robinson BS, Silva JC, Stokes MP, Brosius AD, Baumann A, Buckbinder L.

J Proteomics. 2010 May 7;73(7):1306-20. doi: 10.1016/j.jprot.2010.01.011. Epub 2010 Jan 28.

PMID:
20116462
20.

B cell receptor-induced phosphorylation of Pyk2 and focal adhesion kinase involves integrins and the Rap GTPases and is required for B cell spreading.

Tse KW, Dang-Lawson M, Lee RL, Vong D, Bulic A, Buckbinder L, Gold MR.

J Biol Chem. 2009 Aug 21;284(34):22865-77. doi: 10.1074/jbc.M109.013169. Epub 2009 Jun 26.

21.

Sulfoximine-substituted trifluoromethylpyrimidine analogs as inhibitors of proline-rich tyrosine kinase 2 (PYK2) show reduced hERG activity.

Walker DP, Zawistoski MP, McGlynn MA, Li JC, Kung DW, Bonnette PC, Baumann A, Buckbinder L, Houser JA, Boer J, Mistry A, Han S, Xing L, Guzman-Perez A.

Bioorg Med Chem Lett. 2009 Jun 15;19(12):3253-8. doi: 10.1016/j.bmcl.2009.04.093. Epub 2009 Apr 24.

PMID:
19428251
22.

Structural characterization of proline-rich tyrosine kinase 2 (PYK2) reveals a unique (DFG-out) conformation and enables inhibitor design.

Han S, Mistry A, Chang JS, Cunningham D, Griffor M, Bonnette PC, Wang H, Chrunyk BA, Aspnes GE, Walker DP, Brosius AD, Buckbinder L.

J Biol Chem. 2009 May 8;284(19):13193-201. doi: 10.1074/jbc.M809038200. Epub 2009 Feb 25.

23.

Octahydrophenanthrene-2,7-diol analogues as dissociated glucocorticoid receptor agonists: discovery and lead exploration.

Robinson RP, Buckbinder L, Haugeto AI, McNiff PA, Millham ML, Reese MR, Schaefer JF, Abramov YA, Bordner J, Chantigny YA, Kleinman EF, Laird ER, Morgan BP, Murray JC, Salter ED, Wessel MD, Yocum SA.

J Med Chem. 2009 Mar 26;52(6):1731-43. doi: 10.1021/jm801512v.

PMID:
19239259
24.

Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formation.

Walker DP, Bi FC, Kalgutkar AS, Bauman JN, Zhao SX, Soglia JR, Aspnes GE, Kung DW, Klug-McLeod J, Zawistoski MP, McGlynn MA, Oliver R, Dunn M, Li JC, Richter DT, Cooper BA, Kath JC, Hulford CA, Autry CL, Luzzio MJ, Ung EJ, Roberts WG, Bonnette PC, Buckbinder L, Mistry A, Griffor MC, Han S, Guzman-Perez A.

Bioorg Med Chem Lett. 2008 Dec 1;18(23):6071-7. doi: 10.1016/j.bmcl.2008.10.030. Epub 2008 Oct 11.

PMID:
18951788
25.

Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis.

Buckbinder L, Crawford DT, Qi H, Ke HZ, Olson LM, Long KR, Bonnette PC, Baumann AP, Hambor JE, Grasser WA 3rd, Pan LC, Owen TA, Luzzio MJ, Hulford CA, Gebhard DF, Paralkar VM, Simmons HA, Kath JC, Roberts WG, Smock SL, Guzman-Perez A, Brown TA, Li M.

Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10619-24. Epub 2007 May 30.

26.

NF-kappaB RelA phosphorylation regulates RelA acetylation.

Chen LF, Williams SA, Mu Y, Nakano H, Duerr JM, Buckbinder L, Greene WC.

Mol Cell Biol. 2005 Sep;25(18):7966-75.

27.

The glucocorticoid receptor: molecular mechanism and new therapeutic opportunities.

Buckbinder L, Robinson RP.

Curr Drug Targets Inflamm Allergy. 2002 Jun;1(2):127-36. Review.

PMID:
14561195
28.

FGF signaling antagonizes cytokine-mediated repression of Sox9 in SW1353 chondrosarcoma cells.

Schaefer JF, Millham ML, de Crombrugghe B, Buckbinder L.

Osteoarthritis Cartilage. 2003 Apr;11(4):233-41.

29.

The glucocorticoid receptor: molecular mechanisms and new therapeutic opportunities.

Buckbinder L.

Inflamm Res. 2002 Apr;51(4):167-9. No abstract available.

PMID:
12058952
30.

PA26, a novel target of the p53 tumor suppressor and member of the GADD family of DNA damage and growth arrest inducible genes.

Velasco-Miguel S, Buckbinder L, Jean P, Gelbert L, Talbott R, Laidlaw J, Seizinger B, Kley N.

Oncogene. 1999 Jan 7;18(1):127-37.

31.

The p53/IGF-1 receptor axis in the regulation of programmed cell death.

Neuberg M, Buckbinder L, Seizinger B, Kley N.

Endocrine. 1997 Aug;7(1):107-9. Review.

PMID:
9449044
32.

The p53 tumor suppressor targets a novel regulator of G protein signaling.

Buckbinder L, Velasco-Miguel S, Chen Y, Xu N, Talbott R, Gelbert L, Gao J, Seizinger BR, Gutkind JS, Kley N.

Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):7868-72.

33.

Induction of the growth inhibitor IGF-binding protein 3 by p53.

Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, Kley N.

Nature. 1995 Oct 19;377(6550):646-9.

PMID:
7566179
34.

Gene regulation by temperature-sensitive p53 mutants: identification of p53 response genes.

Buckbinder L, Talbott R, Seizinger BR, Kley N.

Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10640-4.

35.

Expression of the Xenopus laevis prolactin and thyrotropin genes during metamorphosis.

Buckbinder L, Brown DD.

Proc Natl Acad Sci U S A. 1993 May 1;90(9):3820-4.

36.

Thyroid hormone-induced gene expression changes in the developing frog limb.

Buckbinder L, Brown DD.

J Biol Chem. 1992 Dec 25;267(36):25786-91.

37.

The initiator directs the assembly of a transcription factor IID-dependent transcription complex.

Carcamo J, Buckbinder L, Reinberg D.

Proc Natl Acad Sci U S A. 1991 Sep 15;88(18):8052-6.

39.

Phosphorylation of cellular proteins regulates their binding to the cAMP response element.

Merino A, Buckbinder L, Mermelstein FH, Reinberg D.

J Biol Chem. 1989 Dec 15;264(35):21266-76.

40.

Factors involved in specific transcription by mammalian RNA polymerase II. Role of factors IID and MLTF in transcription from the adenovirus major late and IVa2 promoters.

Carcamo J, Lobos S, Merino A, Buckbinder L, Weinmann R, Natarajan V, Reinberg D.

J Biol Chem. 1989 May 5;264(13):7704-14.

41.

EivF, a factor required for transcription of the adenovirus EIV promoter, binds to an element involved in EIa-dependent activation and cAMP induction.

Cortes P, Buckbinder L, Leza MA, Rak N, Hearing P, Merino A, Reinberg D.

Genes Dev. 1988 Aug;2(8):975-90.

42.

Supplemental Content

Loading ...
Support Center